BRCA2 and breast carcinoma: To compute this RR estimate, Edwards et al (2003) used the average of the estimated prevalence (i.e., 0.12 and 0.07%) of germline disease-associated BRCA2 mutations in the general UK population, which was indirectly estimated from two prior studies of breast cancer in the UK (Peto et al, 1999; Antoniou et al, 2002).